PDLIM7 and nasopharyngeal carcinoma: Furthermore, LMP1 was found to activate both mTORC1 and mTORC2 pathways in EBV-driven NPC, and the knockdown of mTORC1 increased NPC treatment susceptibility in previously treatment-resistant NPC [44].